Answer
Nuvaxovid JN.1 should only be considered during pregnancy when potential benefits outweigh potential risks for the mother and fetus; experience with Nuvaxovid in pregnant women is limited, while animal studies do not indicate harmful effects on pregnancy, embryo/fetal development, birth or postnatal development.
Sources for this answer
- Nuvaxovid JN.1 dispersion for injection in pre-filled syringeSANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 4Document updated
Sources checked